'Optimising the management of prostate cancer' was the Takeda-sponsoredBAUS satellite symposium held at the British Association of UrologicalSurgeons' Annual Meeting in Glasgow on 27 June 2012.

The meeting provided expert opinion and debate on the management of prostate cancer in light of recent developments in treatment options and a changing NHS.

The symposium was chaired by Mr Ben Challacombe, and expert and lively presentations were given by Professor Noel Clarke, Dr Amit Bahl, Mr Raj Persad and Mr Dan Burke.

The meeting and associated materials (webcast, interactive PDF and CPD questions) were organised and funded by Takeda. The speakers retained editorial control of the content. The content of the meeting and the webcast comprises the views of the authors and not necessarily those of the BJUI or Takeda.

From this page you can view the webcast, the interactive PDF (which contains the speakers' summaries of their presentations) and complete the CPD questions the speakers have produced based on their talks.

Interactive PDF of the meeting report
Click here to view a PDF of the meeting report which contains the speakers' presentation summaries.


Click on the title to view

Introduction, Mr Ben Challacombe

Recent developments in medical therapy for prostate cancer, Professor Noel Clarke

How will these developments affect the current treatment paradigm/sequencing of therapy? Dr Amit Bahl and Mr Raj Persad

The changing NHS: how to optimise service delivery in the QIPP era, Mr Dan Burke

CPD Questions 

Complete a series of questions relating to the presentations here. You can download a certificate on successful completion of the test.

Select the correct answer (or answers) to the following statements (there may be more than one correct response to each question). 

    Recent developments in medical therapy for prostate cancer (Professor Noel Clarke)

  1. In the TROPIC trial comparing cabazitaxel and mitoxantrone as second-line therapy for castrate-resistant prostate cancer, what proportions of patients remained alive after two years?
  2. In the COU-AA-302 trial in patients with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who had not previously received chemotherapy, by how much did abiraterone increase radiographic progression-free survival compared with placebo?
  3. Which of these statements about MDV 3100 is true?
  4. In the ALSYMPCA trial comparing radium-223 chloride (Alpharadin) with best standard of care plus placebo:
  5. Phase III trials of denosumab in men with castrate-resistant prostate cancer have shown that:
  6. How will these developments affect the current treatment paradigm/sequencing of therapy? (Dr Amit Bahl and Mr Raj Persad)

  7. The radio-isotope which has shown an improvement in overall survival in a phase III trial done with metastatic castrate-resistant prostate cancer patients is:
  8. As per the EAU guidelines, the castrate serum level of testosterone is defined as:
  9. In the post-docetaxel metastatic castrate-resistant prostate cancer the proven chemotherapy agent with overall survival benefit is:
  10. The current licensed indication for abiraterone acetate in metastatic castrate-resistant prostate cancer is in the following setting:
  11. According to NICE Guidelines on the management of prostate cancer, the following prostate cancer patients should be managed by multidisciplinary urological cancer teams:
  12. The changing NHS: how to optimise service delivery in the QIPP era (Mr Dan Burke)

  13. QIPP Stands for
  14. What is the estimated value of savings required by 2014 / 2015?
  15. What is the average annual change in productivity in the NHS between the years 2000-2008?
  16. What is the predicted annual change in productivity required to achieve the required financial savings?
  17. The Enhanced Recovery Programme is estimated to save how many bed days a year?

CPD REVIEWS: Optimising the management of prostate cancer

View or Add Comments

                                                                     Date of preparation November 2012 PS111130s 

Date added to bjui.org: 04/12/2012 (publication information)

Add your Comment

Please note that all submitted comments will be reviewed by the BJUI Web Team before they are considered for publishing on the site. Comments may take up to 48 hours to go live. If you have made a comment which has not appeared live after this time and you wish to discuss this matter further, please contact us.

The Add your Comment facility is only available to Registrants and Members. If you would like to Add a Comment, please make sure that you are logged in. If you would like to register on the site, please click here.

Welcome to the BJUI web site
News Ticker

Associated Societies
  • Urological Society of Australia and New Zealand